AT1 FY21 - General Discussion + FA, page-163

Did anyone manage to take a look at GSS comparative questions I posed up above?

I had a look again this weekend and their current trajectory seems similar to AT1's coming future qtrs Also similar to AT1, they are effectively benefitting from Covid19 exposure to showcase their tech in global markets in accelerated manned; benefits that would have taken years otherwise to penetrate at traditional biomed expansion speed.

Nothing wrong with their financials, with the growth + revenue gains.....but they are not having any further Covid19 related 'excitement' or SP growth (it actually fell a few % after I posted Qs above), despite the revenue substantially growing last 2 Qtrs.......it made me wonder even if AT1 sells everything it makes in FY21 for 60% margins= tremendous result = the market will still be like 'meh, as expected, nothing to see here' type reply..